, Annexe 3 : Gènes pour lesquels deux mutations ou plus ont été identifiées entre des échantillons différents

, Voies de régulation biologiques des ostéosarcomes, vol.4, p.39

G. Ottaviani and N. Jaffe, The epidemiology of osteosarcoma, Cancer Treat. Res, vol.152, pp.3-13, 2009.

A. J. , Osteosarcoma: A Meta-Analysis and Review of the Literature, The American Journal of Orthopedics, vol.44, pp.547-553, 2015.

G. Bacci, Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution, Cancer, vol.106, pp.1154-1161, 2006.

S. C. Kaste, Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity, Pediatr Blood Cancer, vol.43, pp.723-728, 2004.

J. C. Clark, C. R. Dass, and P. F. Choong, A review of clinical and molecular prognostic factors in osteosarcoma, J. Cancer Res. Clin. Oncol, vol.134, pp.281-297, 2008.

G. Bacci, Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute, Oncol. Rep, vol.9, pp.171-175, 2002.

K. R. Duchman, Y. Gao, and B. J. Miller, Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database, Cancer Epidemiology, vol.39, pp.593-599, 2015.

S. S. Bielack, Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols, J. Clin. Oncol, vol.20, pp.776-790, 2002.

A. M. Davis, R. S. Bell, and P. J. Goodwin, Prognostic factors in osteosarcoma: a critical review, J. Clin. Oncol, vol.12, pp.423-431, 1994.
DOI : 10.1200/jco.1994.12.2.423

J. Bramer, .. M. Van-linge, J. H. Grimer, R. J. Scholten, and R. J. , Prognostic factors in localized extremity osteosarcoma: a systematic review, Eur J Surg Oncol, vol.35, pp.1030-1036, 2009.
DOI : 10.1016/j.ejso.2009.01.011

K. Zs, Classification, imaging, biopsy and staging of osteosarcoma., Classification, imaging, biopsy and staging of osteosarcoma, Indian J Orthop, vol.48, pp.238-246, 2014.

M. J. Klein, G. P. Siegal, and . Osteosarcoma, Anatomic and Histologic Variants, American Journal of Clinical Pathology, vol.125, pp.555-581, 2006.

A. Gomez-brouchet, Rôle du pathologiste dans la prise en charge des tumeurs osseuses primitives malignes : ostéosarcomes et tumeurs de la famille Ewing après traitement néoadjuvant, Annales de Pathologie, vol.31, pp.455-465, 2011.
DOI : 10.1016/j.annpat.2011.10.009

M. P. Link, The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity, N. Engl. J. Med, vol.314, pp.1600-1606, 1986.

M. P. Link, Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study, Clin. Orthop. Relat. Res, vol.8, p.14, 1991.

,. Le-deley, SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, European Journal of Cancer, vol.43, pp.752-761, 2007.

G. Bacci, Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy, J Bone Joint Surg Br, vol.84, pp.88-92, 2002.
DOI : 10.1302/0301-620x.84b1.0840088

G. Bacci, Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report, J. Clin. Oncol, vol.18, pp.4016-4027, 2000.

S. S. Bielack, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial, J Clin Oncol, vol.33, pp.2279-2287, 2015.

N. M. Marina, Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial, Lancet Oncol, vol.17, pp.1396-1408, 2016.

M. W. Bishop, K. A. Janeway, and R. Gorlick, Future directions in the treatment of osteosarcoma, Curr. Opin. Pediatr, vol.28, pp.26-33, 2016.

N. Gokgoz, Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma, Cancer, vol.92, pp.2181-2189, 2001.

T. Marees, Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up, J. Natl. Cancer Inst, vol.100, pp.1771-1779, 2008.

K. Rickel, F. Fang, and J. Tao, Molecular genetics of osteosarcoma, Bone, 2016.

M. Kansara, M. W. Teng, M. J. Smyth, and D. M. Thomas, Translational biology of osteosarcoma, Nat Rev Cancer, vol.14, pp.722-735, 2014.

M. S. Lawrence, Mutational heterogeneity in cancer and the search for new cancerassociated genes, Nature, vol.499, pp.214-218, 2013.

P. Ja, Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma, Proc Natl Acad Sci U S A, vol.111, pp.5564-73, 2014.

M. Kovac, Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency, Nat Commun, vol.6, 2015.

J. A. Livingston, Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations, JCO, vol.35, pp.11019-11019, 2017.

S. G. Gaffney and J. P. Townsend, PathScore: a web tool for identifying altered pathways in cancer data, Bioinformatics, vol.32, pp.3688-3690, 2016.

X. Chen, Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma, Cell Rep, vol.7, pp.104-112, 2014.

J. Hedegaard, Next-generation sequencing of RNA and DNA isolated from paired freshfrozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue, PLoS ONE, vol.9, p.98187, 2014.

I. Ferrer, Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study, Brain Pathol, vol.17, pp.297-303, 2007.

A. Guyard, DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks, Virchows Arch, vol.471, pp.491-500, 2017.

C. Chiappetta, Whole-exome analysis in osteosarcoma to identify a personalized therapy, Oncotarget, vol.8, pp.80416-80428, 2017.

C. Alkan, B. P. Coe, and E. E. Eichler, Genome structural variation discovery and genotyping, Nat Rev Genet, vol.12, pp.363-376, 2011.

R. Beroukhim, The landscape of somatic copy-number alteration across human cancers, Nature, vol.463, pp.899-905, 2010.

R. E. Windsor, S. J. Strauss, C. Kallis, N. E. Wood, and J. S. Whelan, Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study, Cancer, vol.118, pp.1856-1867, 2012.

X. Gao, X. Le, and D. B. Costa, The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer, Expert Rev Anticancer Ther, vol.16, pp.383-390, 2016.

H. A. Yu, Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing, Ann. Oncol, vol.25, pp.423-428, 2014.

C. Massard, High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov, vol.7, pp.586-595, 2017.

, Meeting Library | Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfilER Study, p.28, 2017.

D. Gonzalez, BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel, Br. J. Dermatol, vol.168, pp.700-707, 2013.

A. Prahallad, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, vol.483, pp.100-103, 2012.

E. Mosca, Systems biology of the metabolic network regulated by the Akt pathway, Biotechnol. Adv, vol.30, pp.131-141, 2012.

J. Girouard, M. Lafleur, S. Parent, V. Leblanc, and E. Asselin, Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells, Gynecologic Oncology, vol.128, pp.335-343, 2013.

J. Zhu, Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study, Exp Ther Med, vol.13, pp.2862-2866, 2017.

G. Sun, PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, Oncol. Rep, vol.37, pp.3536-3542, 2017.

X. Li, Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63, Tumour Biol, vol.36, pp.9365-9372, 2015.

W. Vainchenker and S. N. Constantinescu, JAK/STAT signaling in hematological malignancies, Oncogene, vol.32, pp.2601-2613, 2013.

J. Yan, Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma, Mol Med Rep, vol.12, pp.498-502, 2015.

D. T. Le, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N. Engl. J. Med, vol.372, pp.2509-2520, 2015.

D. T. Le, Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, pp.409-413, 2017.